IQV · Iqvia Holdings Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted Earnings per Share non-GAAP | $6.04 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $1.93B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted Net Income non-GAAP | $1.02B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Free Cash Flow non-GAAP | $851M | Six Months Ended June 30, 2026 | — |
|
|
|||
| R&D Solutions contracted backlog | $34.2B | As of June 30, 2026 | — |
| R&D Solutions Net New Bookings | $3.15B | second quarter of 2026 | — |
|
|
|||
| Book-to-bill ratio | 1.04 | Q1 2026 | — |
|
|
|||
| Trailing-twelve-month book-to-bill ratio | 1.11 | Q1 2026 | — |
| Net Leverage Ratio non-GAAP | 3.63 | as of December 31, 2025 | — |
| R&D Solutions quarterly bookings | $2.7B | the fourth quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IQV
this stock
Iqvia Holdings Inc.
|
$40.26B | +6.5% | +41.6% | 30.0 | 2.7% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.80B | +1.7% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -7.6% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$45.29B | +36.1% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -18.2% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IQV | -1.6% | +19.1% | +48.3% | +2.1% | +6.5% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | -1.2% | +16.5% | +37.5% | -0.6% | -6.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.